Biologics Market: A Brave New World for U.S. Drug Companies
(Thomson Reuters ONE) -
Thomson Reuters names key players in market and discusses the challenges they
face
Philadelphia, PA, London, UK, February 3, 2011 - The biologics sector is set for
an unprecedented level of activity, according to a new report released today by
the Generics and API Intelligence team at Thomson Reuters.
According to the report, during the past five years, U.S. companies have
dramatically increased their biologics development, with nearly 6,000 clinical
trials with a biological intervention being reported since 2005. With this
increase have come new government regulations promoting competition in this
sector.
The Thomson Reuters report, What You Need to Know About the Follow-On Biologic
Market in the U.S.: Implications, Strategies, and Impact, examines recent
regulations and paints a picture of how companies are entering and navigating
the evolving biologics landscape.
"Combined sales totaling $30 billion last year, coupled with a recently
introduced abbreviated approval pathway for follow-on biologics and an impending
patent cliff for blockbuster drugs, makes the biologics arena very enticing to
pharmaceutical companies and generics alike," notes Andrew Bourgoin,
pharmaceutical research analyst at Thomson Reuters. "With the follow-on
biologics market still in its infancy and ever-evolving, companies need to be
nimble - adaptation to change will be critical for players in this area to
succeed."
Thomson Reuters turned to its Generic and API intelligence team to examine the
implications new regulation has on the biologics market, strategies research
companies can use to compete in this market and the potential impact increased
biologics development could have on the U.S.
In this white paper, you will find:
* Information about the Biologics Price Competition and Innovation Act and how
it affects patent litigation, exclusivity and substitution
* Best practices of cost-cutting and strategic-alliance development.
* A glimpse at the companies expected to compete in the U.S. market.
* Comparisons between biosimilar applications and Biologic Liscense
Application processes.
To download the white paper, please visit:
http://science.thomsonreuters.com/info/newport_whitepapers/
About Thomson Reuters Generic and API Intelligence
Built on more than a decade's experience supplying solutions to meet critical
business challenges in the highly competitive and global generic and API
markets, Thomson ReutersNewport products are now used by more than 250 of the
world's leading generic companies and API manufacturers operating in 50
countries around the world. Thomson Reuters Newport Premium(TM) integrates
intelligence on more than 40,000 launched products with more than 300,000 brand
names containing over 10,000 different active ingredients and over 20,000
corporate groups involved with manufacturing and marketing dose products of both
small molecule and biologic active ingredients.
For more information on Newport Premium, please
visit:http://thomsonreuters.com/products_services/science/science_products/a-
z/newport_premium_generics
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial, legal, tax and accounting, healthcare and science and media markets,
powered by the world's most trusted news organization. With headquarters in New
York and major operations in London and Eagan, Minnesota, Thomson Reuters
employs 55,000 people and operates in over 100 countries. For more information,
go towww.thomsonreuters.com.
CONTACTS
Paul Sandell
Manager, PR & Communications
Healthcare & Science
+44 (0)207 433 4704
paul.sandell(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1484809]
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2011 - 07:01 Uhr
Sprache: Deutsch
News-ID 51010
Anzahl Zeichen: 4932
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biologics Market: A Brave New World for U.S. Drug Companies"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
